JP2024523003A5 - - Google Patents
Info
- Publication number
- JP2024523003A5 JP2024523003A5 JP2023574779A JP2023574779A JP2024523003A5 JP 2024523003 A5 JP2024523003 A5 JP 2024523003A5 JP 2023574779 A JP2023574779 A JP 2023574779A JP 2023574779 A JP2023574779 A JP 2023574779A JP 2024523003 A5 JP2024523003 A5 JP 2024523003A5
- Authority
- JP
- Japan
- Prior art keywords
- dll3
- domain
- trispecific protein
- ligand
- delta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196619P | 2021-06-03 | 2021-06-03 | |
| US63/196,619 | 2021-06-03 | ||
| US202163288939P | 2021-12-13 | 2021-12-13 | |
| US63/288,939 | 2021-12-13 | ||
| US202263345150P | 2022-05-24 | 2022-05-24 | |
| US63/345,150 | 2022-05-24 | ||
| PCT/US2022/031919 WO2022256500A2 (en) | 2021-06-03 | 2022-06-02 | Dll3 targeting trispecific proteins and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523003A JP2024523003A (ja) | 2024-06-25 |
| JP2024523003A5 true JP2024523003A5 (https=) | 2025-06-10 |
Family
ID=84323573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574779A Pending JP2024523003A (ja) | 2021-06-03 | 2022-06-02 | Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240218063A1 (https=) |
| EP (1) | EP4347637A4 (https=) |
| JP (1) | JP2024523003A (https=) |
| AU (1) | AU2022286407A1 (https=) |
| CA (1) | CA3220884A1 (https=) |
| WO (1) | WO2022256500A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2024215875A2 (en) * | 2023-04-14 | 2024-10-17 | Harpoon Therapeutics, Inc. | Compositions and methods for enhancing anti-tumor immunity |
| EP4712977A1 (en) | 2023-05-19 | 2026-03-25 | Boehringer Ingelheim International GmbH | Uses of t cell engaging proteins in the treatment of cancer |
| WO2025085761A1 (en) * | 2023-10-19 | 2025-04-24 | Harpoon Therapeutics, Inc. | Dll3 targeting trispecific proteins and methods of use |
| WO2025201493A1 (zh) * | 2024-03-29 | 2025-10-02 | 诺纳生物（苏州）有限公司 | Dll3结合分子及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023330A2 (pt) * | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
-
2022
- 2022-06-02 EP EP22816833.2A patent/EP4347637A4/en active Pending
- 2022-06-02 AU AU2022286407A patent/AU2022286407A1/en active Pending
- 2022-06-02 JP JP2023574779A patent/JP2024523003A/ja active Pending
- 2022-06-02 CA CA3220884A patent/CA3220884A1/en active Pending
- 2022-06-02 WO PCT/US2022/031919 patent/WO2022256500A2/en not_active Ceased
-
2023
- 2023-11-30 US US18/525,463 patent/US20240218063A1/en active Pending